Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros
Go back to Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros| Actinium Pharmaceuticals, Inc. (NYSE: ATNM) | Delayed: 1.08 -0.03 (2.7%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.11 | 52 Week High | $3.50 | |||
| Open | $1.11 | 52 Week Low | $0.86 | |||
| Day High | $1.14 | P/E | N/A | |||
| Day Low | $1.06 | EPS | $-7.61 | |||
| Volume | 197,095 | |||||
